PolyMedix Successfully Completes Phase 1B Clinical Study With Novel Antibiotic PMX-30063 - MarketWatch.
PMX-30063, a small-molecule mimetic of host defense proteins, has a novel mechanism of action distinct from other antibiotics, which is believed to make bacterial resistance unlikely to develop. PolyMedix is planning to initiate a Phase 2 clinical trial with PMX-30063 in patients with Staph infections in the second quarter of 2010. PolyMedix will host a webcast on Tuesday, April 6, 2010 at 10:00 A.M. ET. The webcast will be available at http://www.investorcalendar.com/ClientPage.asp?ID=156938. Top-line results from this study demonstrated: -- The dose-limiting total daily dose of PMX-30063 in healthy subjects was the same regardless of whether PMX-30063 was administered every 12 or 24 hours. -- Doses of PMX-30063 below the dose-limiting total daily dose killed Staph bacteria, including MRSA, in human serum in blood samples drawn from subjects in the study. -- Dose-limiting effects were generally seen at levels higher than anticipated therapeutic levels. -- Doses administered in the study exceeded theoretical efficacious levels predicted by animal models as well as dose levels which demonstrated bactericidal activity in blood drawn from healthy subjects.
